Journal of Medicinal Chemistry · 2011 · 30 citations · 40 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryEnzymologyMolecular PharmacologyAllosteric Drug DesignEnzyme FunctionEnzyme InhibitionLigand BindingAdenosine Monophosphate-activated Protein Kinase PathwayAllosteric Kinase InhibitorsConserved Structural MotifsEnzyme Inhibitor DiscoveryKinase InhibitorsNon-nucleoside InhibitorsNonnucleoside InhibitorsProtein Kinase Inhibitors
Adenosine kinase (AK) catalyzes the phosphorylation of adenosine (Ado) to AMP by means of a kinetic mechanism in which the two substrates Ado and ATP bind the enzyme in a binary and/or ternary complex, with distinct protein conformations. Most of the described inhibitors have Ado-like structural motifs and are nonselective, and some of them (e.g., the tubercidine-like ligands) are characterized by a toxic profile. We have cloned and expressed human AK (hAK) and searched for novel non-substrate-like inhibitors. Our efforts to widen the structural diversity of AK inhibitors led to the identification of novel non-nucleoside, noncompetitive allosteric modulators characterized by a unique molecular scaffold. Among the pyrrolobenzoxa(thia)zepinones (4a-qq) developed, 4a was identified as a non-nucleoside prototype hAK inhibitor. 4a has proapoptotic efficacy, slight inhibition of short-term RNA synthesis, and cytostatic activity on tumor cell lines while showing low cytotoxicity and no significant adverse effects on short-term DNA synthesis in cells.
40
Receptors for Purines and Pyrimidines
Geoffrey Burnstock, Alexei Verkhratsky · 2012 · 4K citations
Medicine, Biochemistry, Pharmacology +10
A semiempirical free energy force field with charge‐based desolvation
Ruth Huey, Garrett M. Morris, Arthur J. Olson et al. · Journal of Computational Chemistry · 2007 · 2.2K citations · Full text
A hierarchy of timescales in protein dynamics is linked to enzyme catalysis
Katherine A. Henzler‐Wildman, Ming Lei, Vu Thai et al. · Nature · 2007 · 1.1K citations